Table 2.
Number and incidence rate (per 1000 person-years) of tests and SARS-CoV-2 infection (positive test) following second-dose vaccination according to vaccination schedule.
| Heterologous | Homologous | HR/IRR | |||
|---|---|---|---|---|---|
| N / Mean | IR / SD | N / Mean | IR / SD | [95% CI] | |
| Tested | 4874 | 2.21/1000 py | 5134 | 2.35/1000 py | n/a |
| Number of tests (overall) | 0.82 | 1.65 | 0.87 | 1.68 | 1.01 [0.96–1.06] |
| N of tests among the tested | 2.42 | 2.04 | 2.44 | 2.03 | n/a |
| N of PCR tests (overall) | 0.37 | 1.15 | 0.38 | 1.20 | 1.02 [0.96–1.08] |
| N of PCR tests among the tested | 1.86 | 1.98 | 1.87 | 2.08 | n/a |
| N of LFT tests overall | 0.45 | 1.03 | 0.50 | 1.05 | 1.00 [0.96–1.04] |
| N of LFT tests among the tested | 2.18 | 1.17 | 2.17 | 1.07 | n/a |
| SARS-CoV-2 infection | 464 | 0.18/1000 py | 694 | 0.27/1000 py | 0.66 [0.59–0.74] |
CI confidence interval, HR hazard ratio, IR incidence rate, IRR incidence rate ratio, N number, py person-years of follow-up, SD standard deviation.